Use of recombinant factor VIIa in symptomatic intracerebral hemorrhage following intravenous thrombolysis [PDF]
Clinics and Practice, 2015 Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial
Shadi Yaghi +4 more
doaj +2 more sources
Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients [PDF]
Korean Journal of Pediatrics, 2016 Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders.
Jeong A Park
doaj +2 more sources
Recombinant Factor VIIA. [PDF]
Med J Armed Forces India, 2009 Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of hemophilic patients with inhibitors and then used successfully for treating hemorrhages in patients with acquired hemophilia. In the last few years, along with the improvement in the knowledge of its mechanisms of action, rFVIIa has also been used with benefit as a “
Kinra P, Kumar H.
europepmc +4 more sources
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage [PDF]
BMC Neurology, 2008 Background Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought
Eckman Mark H, Kissela Brett M
doaj +2 more sources
Recombinant factor VIIa: new insights into the mechanism of action through product innovation [PDF]
Research and Practice in Thrombosis and HaemostasisManagement of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa).
Miguel A. Escobar +9 more
doaj +2 more sources
The utility of recombinant factor VIIa as a last resort in trauma [PDF]
World Journal of Emergency Surgery, 2012 Introduction The use of recombinant factor VII (rFVIIa) as a last resort for the management of coagulopathy when there is severe metabolic acidosis during large bleedings in trauma might be deemed inappropriate.
Mamtani Rishi +5 more
doaj +2 more sources
Pregnancy and Delivery Management With Recombinant Factor VIIa in a Glanzmann Thrombasthenia Patient: A Case Report. [PDF]
Cureus, 2022 Enciso L +3 more
europepmc +3 more sources
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms. [PDF]
J Thromb Haemost, 2020 Keshava S +3 more
europepmc +3 more sources
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage. [PDF]
Springerplus, 2014 Yampolsky N +4 more
europepmc +3 more sources
Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding [PDF]
BMC Infectious Diseases, 2007 Background This report discusses a case of unsuccessful treatment with recombinant factor VIIa (rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa is outlined as well as the need for methods to control ...
Tsakiris Dimitrios A +3 more
doaj +2 more sources